Multifocal/multicentric breast cancer connected to a patient's risk of local recurrence

October 28, 2012, Fox Chase Cancer Center

Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.

Though previous researchers have analyzed data on patients with this type of , "there is not a strong consensus on whether or not having multifocal or multicentric breast cancer leads to higher recurrence rates," says Tiffany Tam, MD, an attending physician in the Radiation Department at Fox Chase Cancer Center, who will present new findings about this on October 30 at the American Society for Radiation Oncology's 54th Annual Meeting.

Tam led a team of Fox Chase physicians in a retrospective study designed to investigate for possible differences in outcomes. They found no statistically significant difference in overall survival or distant recurrence, where the cancer spreads to other organs or tissues. However, local recurrence—having cancer return to the same area from which it was surgically removed—occurred more than 2.5 times more often among patients with multifocal/multicentric disease, compared to patients with a single .

Tam and her colleagues analyzed the medical records of 112 women who were treated for multifocal or multicentric breast cancer at Fox Chase between 1983 and 2010. They compared outcomes data from those patients with data from 263 women treated for unifocal disease during the same period. Patients from the two groups were matched by age, gender, and stage at diagnosis. The researchers incorporated data on hormone-receptor status, type of surgery, age, grade, stage, and other therapies into their analyses. Males and patients with ductal carcinoma in situ (DCIS), inflammatory breast cancer, or metastatic disease were all excluded from the study.

Overall survival rates and rates of distant recurrence were roughly equal between both groups. When the researchers accounted for all the variables, they found that multifocal or multicentric breast cancer patients were diagnosed with local recurrences about 2.6 times as often as patients with unifocal disease.

Tam says she was motivated to do the study after treating patients diagnosed with multifocal or multicentric disease. "For those patients who do not have any other indications for post-mastectomy radiation, I wondered whether or not multifocal or multicentric disease should be considered in the decision to offer radiation," she says.

The new study won't change clinical practice guidelines, Tam says, but it suggests that the number of tumors found in the breast perhaps should be considered—along with other risk factors when considering radiation therapy.

"Even though this study suggests having multifocal or multicentric disease leads to increase local recurrence, we cannot draw definite conclusions, as this is just a single institutional small retrospective study. It's an additional factor that oncologists can consider," Tam adds. It's not clear whether or not patients with this type of disease have a more aggressive form of cancer or if they have some other risk factor that makes them more susceptible to developing multiple tumors.

Those patients may benefit from therapy following , for example, to reduce the likelihood of local recurrence, though larger studies are needed to weigh the possible benefits against possible harms.

Related Stories

Recommended for you

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

Potential therapy for treatment-resistant hypothyroidism proves effective in lab study

October 12, 2018
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

Immune cells in triple-negative breast cancer offer potential therapeutic target

October 11, 2018
About 15 percent of breast cancers are classified as triple-negative, lacking receptors for estrogen, progesterone, and Her2. These cancers do not respond to targeted hormonal therapies, and they tend to be particularly aggressive, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.